US · FEMY
Femasys Inc.
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Suwanee, GA 30024
- Website
- femasys.com
Price · as of 2024-12-31
$0.38
Market cap 16.78M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $26.15 | +6,709.9% |
| Intrinsic Value(DCF) | $0.60 | +56.25% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $0.00 | $0.00 | |||
| 2021 | $2.09 | $24.01 | $1.26 | $0.00 | $0.00 |
| 2022 | $1.20 | $18.41 | $0.02 | $0.00 | $0.00 |
| 2023 | $2.04 | $23.62 | $0.13 | $0.00 | $2.39 |
| 2024 | $1.50 | $26.15 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Femasys Inc.'s (FEMY) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $26.15
- Current price
- $0.38
- AI upside
- +6,709.9%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.60
+56.25% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| FEMY | Femasys Inc. | $0.38 | 16.78M | +6,710% | +56% | — | — | -1.78 | 14.49 | 20.50 | -2.29 | — | 14.92 | 66.55% | -1091.75% | -1155.03% | -182.18% | -369.29% | -93.61% | 3.23 | -11.09 | 0.93 | 0.46 | -0.24 | -968.00% | 5197.00% | 7686.00% | -60.49% | -2.27 | -419.54% | 0.00% | 0.00% | 0.00% | -2.10 | -1.85 | 22.95 | -16.97 |
| AIMD | Ainos, Inc. | $1.64 | 7.91M | +1,477% | -27% | — | +6,696% | -1.56 | 1.50 | 1120.96 | -3.32 | — | -2.82 | -153.73% | -66772.17% | -71702.26% | -74.38% | -53.08% | -49.00% | 0.77 | -22.45 | 1.10 | 0.98 | -0.86 | -5357.00% | -8302.00% | 2176.00% | -25.09% | -1.47 | -22.36% | 0.00% | 0.00% | 0.00% | -2.26 | -5.38 | 1512.06 | -3.08 |
| APLM | Apollomics, Inc. | $20.21 | 22.3M | +737% | +1,097% | — | +18,417% | -0.11 | 1.22 | 29.90 | 0.07 | — | 1.89 | 100.00% | -21280.81% | -27201.01% | -233.67% | -2034.57% | -157.28% | 0.20 | -235.40 | 1.39 | 1.34 | 0.21 | -7724.00% | -7588.00% | -3343.00% | -485.92% | -3.88 | -1389.04% | 0.00% | 0.00% | 0.00% | 0.07 | 0.10 | -14.54 | -84.82 |
| BCTX | BriaCell Therapeutics Cor… | $3.82 | 7.2M | — | — | — | — | -0.64 | 0.95 | — | 0.03 | -1.44 | 0.96 | 0.00% | — | — | -343.04% | 1683.01% | -192.49% | 0.00 | -735.71 | 5.01 | 4.63 | 0.39 | 4450.00% | — | 1632.00% | -167.26% | -7.14 | 1742.76% | 0.00% | 0.00% | 56.64% | 0.03 | 0.03 | — | -8.16 |
| COCH | Envoy Medical, Inc. | $0.72 | 15.07M | +3,147% | -23% | — | +2,867% | -1.16 | -1.39 | 116.08 | -2.03 | — | -1.39 | -229.78% | -8558.22% | -9242.22% | 217.79% | 381.46% | -226.68% | -1.04 | -23.60 | 1.24 | 0.84 | -0.72 | -4134.00% | -2880.00% | 977.00% | -72.47% | -2.38 | 374.98% | 9.37% | -10.90% | 9.37% | -2.09 | -2.13 | 179.09 | -39.33 |
| CRIS | Curis, Inc. | $1.14 | 15.61M | +342% | +2% | — | — | -0.42 | -3.06 | 1.68 | -0.03 | — | -1.23 | 99.10% | -408.34% | -397.77% | -634.71% | 156.53% | -73.20% | -0.49 | -72.43 | 1.39 | 1.23 | 0.40 | -2321.00% | 883.00% | 294.00% | -215.59% | -2.08 | 139.03% | 0.00% | 0.00% | 0.00% | -0.03 | -0.03 | 0.12 | -44.91 |
| DARE | Daré Bioscience, Inc. | $1.70 | 16.19M | +12,485% | -31% | — | +2,345% | -6.18 | -4.17 | 2561.95 | -0.46 | — | -4.17 | -146110.22% | -239692.20% | -41430.90% | 73.30% | 135.85% | -18.69% | -0.22 | — | 0.85 | 0.74 | 0.61 | -8843.00% | -9965.00% | -11221.00% | 19.23% | 0.25 | -27.93% | 0.00% | 0.00% | 21.24% | -0.46 | 2.21 | 1090.66 | -14.24 |
| EKSO | Ekso Bionics Holdings, In… | $10.14 | 24.6M | +55% | -60% | — | +814% | -2.12 | 2.75 | 1.94 | -2.68 | -0.27 | 4.87 | 53.48% | -104.12% | -91.37% | -107.62% | -117.46% | -50.02% | 0.29 | -43.13 | 1.63 | 0.98 | -0.15 | 77679.00% | -2860.00% | 2131.00% | -48.31% | -1.37 | -105.67% | 0.91% | -1.90% | 0.91% | -1.97 | -2.19 | 2.05 | -18.15 |
| HBIO | Harvard Bioscience, Inc. | $0.61 | 27.44M | +5,740% | -46% | — | +242% | -2.88 | 0.56 | 0.38 | -51.62 | -1.16 | -8.67 | 58.18% | -6.60% | -13.18% | -18.19% | -5.77% | -9.40% | 0.70 | -1.94 | 0.82 | 0.35 | -27.40 | 24783.00% | -1614.00% | -11556.00% | -5.11% | 0.03 | -1.69% | 0.00% | 0.00% | 0.00% | -12.25 | -41.74 | 0.81 | -0.92 |
| PCSA | Processa Pharmaceuticals,… | $2.17 | 4.92M | — | — | — | — | -0.12 | 0.87 | — | -0.03 | — | 0.87 | 0.00% | — | — | -354.51% | -2381.97% | -262.87% | 0.04 | — | 1.22 | 0.78 | 0.09 | -5436.00% | — | 3945.00% | -761.08% | -7.34 | -2223.27% | 0.00% | 0.00% | 1.08% | -0.03 | -0.03 | — | -49.42 |
| VVOS | Vivos Therapeutics, Inc. | $1.40 | 8.25M | +1,347% | +8,020% | — | — | -1.66 | 2.33 | 1.23 | -1.31 | — | 3.91 | 60.00% | -74.32% | -74.09% | -266.25% | -562.91% | -85.62% | 0.19 | — | 1.50 | 1.34 | 0.45 | -8007.00% | 891.00% | 400.00% | -71.58% | -2.55 | -668.13% | 0.00% | 0.00% | 27.53% | -1.23 | -1.04 | 0.92 | -9.26 |
About Femasys Inc.
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
- CEO
- Kathy Lee-Sepsick
- Employees
- 69
- Beta
- -2.54
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.60 ÷ $0.38) − 1 = +56.25% (DCF, example).